Through its Selective Spectrum technology, Pocared is developing point-of-care diagnostics for on-site analysis of human fluids and specimen, to provide physicians with real-time detection, identification and antibiotic sensitivity of pathogenic bacteria. Pocared plans to launch its first application, which will target medical IVD, within two years.
Elron’s director of business development, Elad Frenkel, said of his company’s investment, “We view Pocared as a highly innovative company presenting an out-of-the-box solution and introducing a disruptive platform technology in the field of real-time IVD.”
